Navigation Links
Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk
Date:10/24/2009

SAN DIEGO, Oct. 24 /PRNewswire-FirstCall/ -- Orexigen® ( )Therapeutics, Inc (Nasdaq: OREX) today announced new data from the COR-I, COR-II and COR-Diabetes trials for Contrave® (bupropion SR/ naltrexone SR) to expand on top-line results announced in July. Contrave is the first of the Company's two late stage candidates for the treatment of obesity. These data were presented during a panel discussion at the 27th Annual Scientific Meeting of The Obesity Society.

These new data show that after completing 56 weeks of therapy with Contrave32:

  • Approximately 34-48% of patients lost at least 10% of their baseline body weight and approximately 17-23% lost at least 15%;
  • Obese patients classified as higher risk for developing cardiovascular disease and diabetes demonstrated significant improvement in markers of cardiometabolic risk such as waist circumference, HDL, and triglycerides;
  • Patients with type 2 diabetes taking Contrave who began the trial with a hemoglobin A1c (HbA1c) level greater than 8% saw a mean HbA1c reduction of 1.1%, which was highly statistically significant compared to placebo;
  • Patients reported an increased ability to control their eating and resist food cravings; and
  • There was no evidence of increased abuse liability.

"These data show that Contrave provides obese patients with meaningful reduction in weight and improvement in important markers of cardiometabolic risk, with even greater improvement seen in patients at higher risk," said Dennis Kim, M.D., Senior Vice President of Medical Affairs. "Results also illustrate the robust glycemic benefit of Contrave in patients who have poorly controlled diabetes, as defined by a hemoglobin A1C level greater than 8.0. These patients experienced a clinically meaningful A1C reduction of 1.1% fro
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
2. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
3. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
4. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
5. Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)
6. Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock
7. Orexigen(R) Therapeutics Prices Public Offering of Common Stock
8. Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results
9. Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients
10. Prime Therapeutics Receives TIPPS Certification
11. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Expectant parents should leave prenatal picture-taking to medical professionals, ... of ultrasound imaging and heartbeat monitors to get "keepsake" ... warns. "Although there is a lack of ... heartbeat monitors, prudent use of these devices by trained ... biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... improve overall health, but a growing body of evidence shows ... review finds. In fact, the benefits were similar to ... researcher Paula Chu, a doctoral candidate at Harvard University,s Health ... trials, found that people randomly assigned to take yoga classes ...
(Date:12/15/2014)... December 15, 2014 Veretekk.com, Inc. announced ... Ocean Avenue. JM Ocean Avenue has secured exclusive ... online automated marketing system. JM Ocean Avenue is ... merger of Ocean Avenue and JM International, with partial ... Billion per year company. , “After nearly 2 decades ...
(Date:12/15/2014)... 2014 OutMarket , a provider ... Social Media Cheat Sheets ,” a guide that exposes ... results on the top ten social media networks. ... drive awareness, engagement, and customer service. It can also ... an impact on new networks and weather constantly changing ...
(Date:12/15/2014)... December 15, 2014 The increase in prevalence ... of the main factors which is contributing to the growth ... the diagnosis and treatment of hearing loss and balance disorders ... three parts - microphone, speaker and amplifier. The global market ... of 6.01% during the period from 2014 to 2019. Some ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... Minn. Mayo Clinic has received investigational ... the Food and Drug Administration ( http://www.fda.gov/ ... mobilize the body,s defense mechanisms to destroy ... first aimed at preventing cancer recurrence. The ...
... News) -- Although not life-threatening, sprains and strains account ... in U.S. emergency departments, according to a new study. ... emergency hotline or scheduled doctor appointments, would spare valuable ... Hospital in Boston, said in the report, recently published ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, ... this week expressed growing concerns over a rise in rates ... New data released Tuesday at the National HIV Prevention Conference ... that 19 percent of gay and bisexual men, 9 percent ...
... Reporter , TUESDAY, Aug. 16 (HealthDay News) -- Almost half ... and the risk of bladder cancer has increased significantly for ... Smokers now face a four times higher risk of ... years ago, that risk was about three times that of ...
... TUESDAY, Aug. 16 (HealthDay News) -- ,Scientists who identified ... a need for gender-specific drug therapies for some diseases. ... blood serum from more than 3,000 people and found ... in lipids and amino acids. The results prove ...
... , TUESDAY, Aug. 16 (HealthDay News) -- Black women ... are less likely to breast-feed, putting them at greater risk ... a new study. The study, published in the ... found the risk for hormone receptor-negative breast cancer was 50 ...
Cached Medicine News:Health News:Mayo Clinic receives FDA approval for ovarian and breast cancer vaccines 2Health News:Sprained Ankles Straining ER Resources, Study Finds 2Health News:Experts Concerned About Rising HIV Rates Among Poor, Minorities 2Health News:Bladder Cancer Risk Even Higher for Smokers Than Thought 2Health News:Bladder Cancer Risk Even Higher for Smokers Than Thought 3Health News:Blacks at Higher Risk for Resistant Breast Cancer: Study 2
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "MEMS Gyroscopes Analog ... Analysis" report to their offering. ... gyroscopes for tactical grade applications made a lot ... term of reliability. They are now accepted in ...
(Date:12/15/2014)... 15, 2014 BerGenBio AS, a ... drug resistant cancers, today announces that it has raised ... from new and existing investors. BerGenBio will ... development of its pipeline of innovative cancer therapeutics, in ... drug candidate, BGB324, a first-in-class selective Axl kinase inhibitor, ...
(Date:12/15/2014)... -- Colorado and Washington State are not ... Oregon , Alaska , ... the November 2014 elections. Photo - ... The benefits of legalizing cannabis are manifold. There ... increased tax revenue for state and local governments, in addition ...
Breaking Medicine Technology:MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2BerGenBio Completes NOK90 Million Fundraising 2CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2
... Aug. 13 BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: ... marketing and distribution partner in Japan, has,submitted a ... Japanese Ministry of Health, Labour and Welfare. ... to bring the first drug,treatment option to MPS ...
... Texas, Aug. 13 Lexicon,Pharmaceuticals, Inc. (Nasdaq: ... an oral presentation at the American Chemical Society ... August 21, 2007,at 2:50 p.m. Eastern Time. The ... serotonin levels by enzyme inhibitors for the,potential treatment ...
Cached Medicine Technology:BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health 2BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health 3BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health 4Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate 2Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate 3
Inquire...
Inquire...
Nature's Remarkable Skin Protector -- Karaya 5 is a natural skin barrier that is particularly well suited for skin problems or for sensitive skin where reactions may have occurred to other types of s...
Superior Skin Care...FlexWear skin barrier provides skin protection for an extended wear time....
Medicine Products: